NCT05372562View on ClinicalTrials.gov

Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Macular Edema
Trial Locations (1)

100191

Peking University Third Hosipital, Beijing

All Listed Sponsors
lead

Peking University

OTHER

NCT05372562 - Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX | Biotech Hunter | Biotech Hunter